VERWENDUNG VON 2-(2-MORPHOLINOPHENYL)GUANIDINDERIVATE ZUR BEHANDLUNG VON DIABETES-KOMPLIKATIONEN

VERWENDUNG VON 2-(2-MORPHOLINOPHENYL)GUANIDINDERIVATE ZUR BEHANDLUNG VON DIABETES-KOMPLIKATIONEN

PCT No. PCT/EP97/06831 Sec. 371 Date Jun. 14, 1999 Sec. 102(e) Date Jun. 14, 1999 PCT Filed Dec. 8, 1997 PCT Pub. No. WO98/26782 PCT Pub. Date Jun. 25, 1998A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example 1,1-dimethyl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JONES, ROBERT BRIAN, MERRYMAN SIMPSON, ANNEMARIE ELIZABETH CLAIRE
Format: Patent
Sprache:ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PCT No. PCT/EP97/06831 Sec. 371 Date Jun. 14, 1999 Sec. 102(e) Date Jun. 14, 1999 PCT Filed Dec. 8, 1997 PCT Pub. No. WO98/26782 PCT Pub. Date Jun. 25, 1998A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate) is used for inhibiting the formation of advanced glycosylation end-products, and for the treatment and/or prophylaxis of long-term complications associated with diabetes, such as atherosclerosis, nephropathy, neuropathy and retinopathy.